Rani Therapeutics Gets Ball Rolling On Oral Stelara Biosimilar

Three Phase I Biosimilar Trials Planned For 2023, Including Stelara And Humira Rivals

 
• By Dean Rudge
  
Image of an IV drip, often used in chemotherapy
Rani is attempting to differentiate from typical infusion biologics • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products